

6 June 2024

A\$18.7m Osteopore, NDCS and A*STAR project hits key milestones

Highlights

- Osteopore's A\$18.7m partnership with Singapore's NDCS and A*STAR to develop next-generation dental implants achieves key milestones.
- The project developed a 3D-printing technology which can successfully combine patented biological additives and polymer compounds.
- The successful combination of the additives and compounds can speed up bone regeneration.
- Adverse reaction testing demonstrated the non-cytotoxicity of successfully combining patented biological additives and polymer compounds.
- Testing for osteogenic differentiation revealed enhanced osteogenic differentiation capabilities.
- The project is now set to advance to in vivo studies of biological models, to gauge the efficacy of bone regeneration.
- The next-generation dental implants provide Osteopore with exposure to the US\$27.55 billion global dental bone graft and membrane substitute market.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to share the exciting progress made by its A\$18.7m clinical-industrial partnership with the National Dental Centre Singapore (NDCS) and the Agency for Science, Technology and Research (A*STAR).

On 13 December 2021, Osteopore announced the signing of an agreement with NDCS and A*STAR to launch an A\$18.7m dental implant project¹.

The project's key milestones – see announcement dated 13 December 2021 – included combining patented biological additives and polymer compounds to test for adverse reactions, osteogenic differentiation to indicate bone growth, and higher osteogenic differentiation to demonstrate faster bone growth.

The Company is pleased to announce the successful development of a 3D-printed technology, which can combine patented biological additives and polymer compounds for dental implants that have the potential to accelerate bone healing.

Adverse reaction testing demonstrated that the successful combination of patented biological additives and polymer compounds was non-cytotoxic, showing no adverse reactions and good biocompatibility.

Moreover, osteogenic differentiation testing showed enhanced viability and osteogenic differentiation capabilities, indicating both osteogenic differentiation and higher osteogenic differentiation.

The next-generation dental implant project is now set to progress towards in vivo studies in biological models.

Commenting on the NDCS and A*STAR partnership and the project's early successes, CEO Dr Yujing Lim said:

"We are excited by the outcomes of this project so far and appreciate the support of our partners at A*STAR and NDCS. We are delighted with the dedication of our partners towards ensuring that project milestones are met."

¹ ASX announcement "Osteopore secures A\$18.7m clinical-industrial partnership", 13 December 2021.

“While we continue to prioritise our objective of commercialising our current products, we are looking forward to working on new technologies – such as the next-generation jaw implant – which supports our long-term vision of becoming the global leader in regenerative medicine,” said Dr Lim.

The global dental bone graft and membrane substitutes market was valued at USD\$11.47 billion in 2023, with a projected value of USD\$27.55 billion by 2030², according to Verified Market Reports.

ENDS

This announcement dated 6 June 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Isaac Stewart

Media & Investor Relations

Purple

E: istewart@purple.au

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

² <https://www.verifiedmarketreports.com/product/dental-membrane-and-bone-graft-substitutes-market-size-and-forecast/>

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement.

This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

